Further, solely deleting or hyper-activating Lyn on its own has little direct influence upon the prevalence of leukaemia or cancer [20,34], but as this enzyme is important for particular neoplasms (reviewed above), it must therefor be concluded that a dysregulation of pathways/substrates/regulators/adaptors, intersected by Lyn, rather than just Lyn itself, is what potentiates these particular cancers and leukaemias. The gene discussed is LYN; the disease is cancer.